Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Phase 4

Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke

NCT07943026 · tracked via the Priya Life Science Italy tracker
Phase
Phase 4
Started
2026-12
Last updated
2026-11-17

Condition(s) studied

Ischemic Stroke

Investigational drug(s) / intervention(s)

Acetylsalicylic acid (ASA)/aspirin 100 mg dailyClopidogrel 75 mg daily →Ticlopidine 250 mg twice daily

Acetylsalicylic acid (ASA)/aspirin 100 mg daily: Aspirin acts as an irreversible inhibitor of COX-1/-2 enzymes, decreasing prostaglandin precursors formation and inhibiting platelet aggregation. It is the most prescribed medication for cardio-cerebrovascular diseases prevention, as this has been the first antiplatelet with demonstrated effectiveness and safety (Rothlisberger and Ovbiagele, 2015).

Clopidogrel 75 mg daily: Clopidogrel works by irreversibly blocking the P2Y12 component of ADP receptors on platelets preventing the activation of GPIIb/IIIa receptor complexes (Rothlisberger and Ovbiagele, 2015).

Ticlopidine 250 mg twice daily: Ticlopidine has a mechanism of action similar to Clopidogrel, as it works by irreversibly blocking the P2Y12 component of ADP receptors on platelets preventing the activation of GPIIb/IIIa receptor complexes. However it takes longer time to reach the maximal effect (Rothlisberger and Ovbiagele, 2015).

Study summary

The TAILOR study aims to determine whether personalized antiplatelet therapy can reduce the risk of recurrent major cardiovascular events in patients who have experienced (a non-cardioembolic ischemic stroke).

Antiplatelet medications, such as aspirin and clopidogrel, are commonly prescribed to prevent stroke recurrence. However, some patients do not respond adequately to these medications and may remain at increased risk of further cardiovascular events.

The study will compare two approaches to antiplatelet therapy: standard care, in which medications are prescribed according to current clinical practice, and personalized care (tailored care), in which treatment is adjusted based on a blood test measuring how effectively the medication inhibits platelet activity.

Participants will be randomly assigned to one of these two treatment strategies and followed for 12 months.

The main hypothesis is that tailoring antiplatelet therapy according to individual platelet response will be more effective than standard care in preventing recurrent ischemic stroke, myocardial infarction, or cardiovascular death. The study will also explore potential differences in treatment response between women and men.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged ≥18 years old * Males and females * Non-cardioembolic ischemic stroke within the previous 14 days * Starting or continuing secondary prevention with single or dual antiplatelet therapy after the index stroke * Written informed consent. Exclusion Criteria: * Known hypersensitivity to aspirin, clopidogrel or ticlopidine, or to any of the excipients. * Concurrent need for anticoagulation for any indication * Contraindication to study drugs * Indications to perform carotid revascularization surgery * Participation in a clinical trial in which an investigational drug was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer * Pregnancy and breastfeeding; WOCBP not using acceptable contraception during the trial period (combined \[estrogen and progestogen containing\] hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device \[IUD\], intrauterine hormone-releasing system \[IUS\], bilateral tubal occlusion. vasectomised partner, sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide) * History of asthma induced by the administration of acetylsalicylates or substances with a similar activity, especially nonsteroidal anti-inflammatory drugs * Active or previous recurrent peptic ulcer and/or gastric/intestinal bleeding, or other types of bleeding such as cerebrovascular hemorrhage. * Bleeding diathesis; coagulation disorders such as hemophilia and thrombocytopenia. * Severe hepatic impairment. * Severe renal impairment * Uncontrolled severe cardiac failure * Methotrexate used at doses equal to or greater than 15 mg/week. Combination with other potentially myelotoxic drugs. Subjects with or who have had leukopenia, thrombocytopenia, or agranulocytosis.

Primary outcome measure(s)

  • Major Cardiovascular Event at 12 months — From randomization to 12 months
    Time to the first occurrence of a composite event comprising ischemic stroke, myocardial infarction, or cardiovascular death within 3 months after randomization. The outcome will be assessed as time to first event (days) and cumulative incidence (percentage of participants experiencing at least one event).

Trial sites (3)

FacilityCityRegionStatus
IRCCS Istituto delle Scienze Neurologiche di Bologna - Azienda USL di Bologna Bologna BO
Ospedale Civile di Baggiovara Modena MO
Ospedale Bufalini - AUSL della Romagna Cesena Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07943026 on ClinicalTrials.gov ↗ ← All trials in Italy